BIOGEN INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.9B | $9.7B | $9.8B | $10.2B | $11.0B |
| Cost of revenue | $2.4B | $2.3B | $2.5B | $2.3B | $2.1B |
| Selling, general & administrative | $2.4B | $2.4B | $2.5B | $2.4B | $2.7B |
| Research and development | $1.8B | $2.0B | $2.4B | $2.2B | $2.5B |
| Operating income | — | — | — | — | $2.8B |
| Interest expense | $267.5M | $250.3M | $246.9M | $246.6M | $253.6M |
| Pretax income | $1.6B | $1.9B | $1.3B | $3.6B | $1.7B |
| Income tax expense | $263.6M | $273.8M | $135.3M | $632.8M | $52.5M |
| Net income | $1.3B | $1.6B | $1.2B | $3.0B | $1.6B |
| Balance Sheet | |||||
| Current assets | $9.0B | $7.5B | $6.9B | $9.8B | $7.9B |
| Total assets | $29.4B | $28.0B | $26.8B | $24.6B | $23.9B |
| Current liabilities | $3.3B | $5.5B | $3.4B | $3.3B | $4.3B |
| Total liabilities | $11.2B | $11.3B | $12.0B | $11.2B | $12.9B |
| Total debt | $6.6B | $6.6B | $7.2B | — | — |
| Stockholders' equity | $18.3B | $16.7B | $14.8B | $13.4B | $10.9B |
| Cash Flow Statement | |||||
| Cash from operations | $2.2B | $2.9B | $1.5B | $1.4B | $3.6B |
| Depreciation and amortization | $779.9M | $673.2M | $494.8M | $518.4M | $487.7M |
| Stock-based compensation | $290.8M | $291.2M | $264.2M | $254.1M | $238.6M |
| Capital expenditure | $153.8M | $153.7M | $277.0M | $240.3M | $258.1M |
| Free cash flow | $2.1B | $2.7B | $1.3B | $1.1B | $3.4B |
| Share repurchases | — | $0 | $0 | $750.0M | $1.8B |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 147.6M · Free float 99.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.